ESCALON MEDICAL CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ESCALON MEDICAL CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Jun 30, 2020 | $9.40M | Sep 28, 2020 |
| FY2020 | Jun 30, 2019 | $9.63M | Sep 28, 2020 |
| FY2014 | Jun 30, 2014 | $5.42M | Sep 26, 2014 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jun 30, 2018 | $11.40M | Sep 28, 2018 |
| FY2018 | Jun 30, 2017 | $11.23M | Sep 28, 2018 |
| FY2017 | Jun 30, 2016 | $11.58M | Sep 28, 2017 |
| FY2016 | Jun 30, 2015 | $13.14M | Oct 12, 2016 |
| FY2014 | Jun 30, 2014 | $12.35M | Sep 29, 2015 |
| FY2014 | Jun 30, 2013 | $11.50M | Sep 26, 2014 |
| FY2013 | Jun 30, 2012 | $11.46M | Sep 20, 2013 |
| FY2012 | Jun 30, 2011 | $25.58M | Sep 26, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $105.5K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($125.3K) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $456.8K | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $18.1K | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | ($52.0K) | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | ($650.3K) | Sep 27, 2021 |
| FY2019 | Jun 30, 2019 | ($250.0K) | Sep 27, 2019 |
| FY2019 | Jun 30, 2018 | $583.7K | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | ($726.9K) | Sep 28, 2018 |
| FY2017 | Jun 30, 2016 | ($1.15M) | Sep 28, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $133.2K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($104.5K) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $478.5K | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($470.1K) | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | ($33.7K) | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | ($1.40M) | Sep 27, 2021 |
| FY2020 | Jun 30, 2019 | ($253.0K) | Sep 28, 2020 |
| FY2019 | Jun 30, 2018 | $204.7K | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | ($626.9K) | Sep 28, 2018 |
| FY2017 | Jun 30, 2016 | ($1.14M) | Sep 28, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $753.1K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $688.2K | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $818.8K | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $991.0K | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | $890.5K | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | $1.12M | Sep 27, 2021 |
| FY2020 | Jun 30, 2019 | $739.8K | Sep 28, 2020 |
| FY2019 | Jun 30, 2018 | $500.3K | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | $1.05M | Sep 28, 2018 |
| FY2017 | Jun 30, 2016 | $1.45M | Sep 28, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $4.62M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $4.56M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $4.18M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $4.09M | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | $3.57M | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | $3.87M | Sep 27, 2021 |
| FY2020 | Jun 30, 2019 | $4.14M | Sep 28, 2020 |
| FY2019 | Jun 30, 2018 | $4.40M | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | $4.60M | Sep 28, 2018 |
| FY2017 | Jun 30, 2016 | $5.07M | Sep 28, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $380.7K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($602.8K) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $325.1K | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($1.05M) | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | $838.7K | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | ($168.5K) | Sep 27, 2021 |
| FY2020 | Jun 30, 2019 | ($472.7K) | Sep 28, 2020 |
| FY2016 | Jun 30, 2016 | ($1.20M) | Oct 12, 2016 |
| FY2016 | Jun 30, 2015 | ($456.5K) | Oct 12, 2016 |
| FY2014 | Jun 30, 2014 | ($622.6K) | Sep 29, 2015 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $3.9K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $40.3K | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $6.7K | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $0 | Oct 13, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $4.99M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $4.76M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $5.31M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $5.17M | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | $5.68M | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | $5.72M | Sep 27, 2021 |
| FY2020 | Jun 30, 2019 | $5.13M | Sep 28, 2020 |
| FY2019 | Jun 30, 2018 | $5.43M | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | $4.98M | Sep 28, 2018 |
| FY2017 | Jun 30, 2016 | $5.53M | Sep 28, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $3.08M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $2.95M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $3.37M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $3.69M | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | $4.22M | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | $4.21M | Sep 27, 2021 |
| FY2020 | Jun 30, 2019 | $2.97M | Sep 28, 2020 |
| FY2019 | Jun 30, 2018 | $3.01M | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | $3.80M | Sep 28, 2018 |
| FY2017 | Jun 30, 2016 | $3.62M | Sep 28, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.92M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $1.81M | Sep 29, 2025 |
| FY2025 | Jun 30, 2023 | $1.93M | Sep 29, 2025 |
| FY2024 | Jun 30, 2022 | $1.48M | Sep 30, 2024 |
| FY2023 | Jun 30, 2021 | $1.46M | Oct 13, 2023 |
| FY2022 | Jun 30, 2020 | $1.51M | Sep 28, 2022 |
| FY2021 | Jun 30, 2019 | $2.16M | Sep 27, 2021 |
| FY2020 | Jun 30, 2018 | $2.41M | Sep 28, 2020 |
| FY2019 | Jun 30, 2017 | $1.18M | Sep 27, 2019 |
| FY2018 | Jun 30, 2016 | $1.91M | Sep 28, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Jun 30, 2017 | $0 | Sep 28, 2017 |
| FY2017 | Jun 30, 2016 | $125.0K | Sep 28, 2017 |
| FY2016 | Jun 30, 2015 | $125.0K | Oct 12, 2016 |
| FY2014 | Jun 30, 2014 | $125.0K | Sep 29, 2015 |
| FY2014 | Jun 30, 2013 | $125.0K | Sep 26, 2014 |
| FY2013 | Jun 30, 2012 | $125.0K | Sep 20, 2013 |
| FY2012 | Jun 30, 2011 | $218.2K | Sep 26, 2012 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($68.44M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($68.54M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($68.42M) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($68.88M) | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | ($68.89M) | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | ($68.84M) | Sep 27, 2021 |
| FY2020 | Jun 30, 2019 | ($68.19M) | Sep 28, 2020 |
| FY2019 | Jun 30, 2018 | ($67.94M) | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | ($68.53M) | Sep 28, 2018 |
| FY2017 | Jun 30, 2016 | ($67.80M) | Sep 28, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $545.8K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $209.0K | Sep 29, 2025 |
| FY2025 | Jun 30, 2023 | $889.7K | Sep 29, 2025 |
| FY2024 | Jun 30, 2022 | $593.9K | Sep 30, 2024 |
| FY2023 | Jun 30, 2021 | $1.65M | Oct 13, 2023 |
| FY2022 | Jun 30, 2020 | $826.0K | Sep 28, 2022 |
| FY2021 | Jun 30, 2019 | $409.7K | Sep 27, 2021 |
| FY2020 | Jun 30, 2018 | $874.0K | Sep 28, 2020 |
| FY2019 | Jun 30, 2017 | $544.1K | Sep 27, 2019 |
| FY2017 | Jun 30, 2016 | $538.1K | Sep 28, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | 0 | Sep 27, 2021 |
| FY2020 | Jun 30, 2019 | 0 | Sep 28, 2020 |
| FY2019 | Jun 30, 2018 | 0 | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | 0 | Sep 28, 2018 |
| FY2016 | Jun 30, 2016 | 0 | Oct 12, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | 0 | Sep 27, 2021 |
| FY2020 | Jun 30, 2019 | 0 | Sep 28, 2020 |
| FY2019 | Jun 30, 2018 | 0 | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | 0 | Sep 28, 2018 |
| FY2016 | Jun 30, 2016 | 0 | Oct 12, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 7.42M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 7.42M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | 7.42M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | 7.42M | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | 7.42M | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | 7.42M | Sep 27, 2021 |
| FY2020 | Jun 30, 2019 | 7.42M | Sep 28, 2020 |
| FY2019 | Jun 30, 2018 | 7.42M | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | 7.53M | Sep 28, 2018 |
| FY2017 | Jun 30, 2016 | 7.53M | Sep 28, 2017 |